Eastman Chemical Company filings document regulatory disclosures for a global specialty materials issuer with publicly traded common stock and outstanding debt securities. Form 8-K reports furnish quarterly and annual operating results, including sales, EBIT, cash flow, segment performance, price-cost conditions, raw-material pressures and updates tied to specialty businesses and methanolysis assets.
Proxy materials describe director elections, board committee matters, executive compensation, say-on-pay voting and shareholder proposals. Other material-event filings record debt issuance under registration statements and indentures, officer and director changes, compensatory arrangements, common stock references and note terms, including interest, maturity and redemption provisions.
Director Humberto P. Alfonso reported acquisitions of phantom stock units under the company's Directors' Deferred Compensation Plan that convert to cash after he leaves the board. On 10/07/2025 he voluntarily deferred 1,178 units (valued at $62.35 each in the filing) and had an automatic deferral of 487 units, for a total of 1,665 newly credited phantom units.
Following these entries, he beneficially owns 53,576 shares (or share-equivalents) in a direct form. The filing notes 1,130 additional units credited since 5/01/2025 from hypothetical reinvestment of dividend equivalents. The units are payable only in cash under the plan.
Eastman Chemical Company disclosed an executive succession and related compensation changes after its Senior Vice President - Chief Technology and Sustainability Officer, Chris M. Killian, notified the company he will retire effective December 31, 2025 for family and health reasons. To lead the transition, Stephen G. Crawford will return as Executive Vice President - Technology Projects on November 3, 2025, then move to Executive Vice President - Chief Technology Officer and Chief Sustainability Officer on January 1, 2026.
Mr. Crawford’s package includes a $705,000 base salary, an annual bonus opportunity at 85% of base (prorated for 2025), an $800,000 sign-on payment to replace forfeited equity and satisfy prior severance obligations, and a restricted stock unit award with a grant-date fair value of $2,200,000 to be granted on or about January 2, 2026. He will also participate in standard executive benefit programs.
Michelle H. Caveness, Senior Vice President and Chief Manufacturing Officer of Eastman Chemical Co. (EMN), reported changes in her beneficial ownership on transactions dated 10/01/2025. She received a payout of 6,715 restricted stock units (RSUs) upon completion of a three-year vesting period, recorded as an acquisition. Simultaneously, 1,636 shares were withheld to satisfy tax liabilities at a reported price of $61.96 per share. After these transactions the filing shows 6,246 shares beneficially owned. The Form 4 was signed by power of attorney on 10/02/2025.
Adrian James Holt, Senior Vice President and Chief Human Resources Officer of Eastman Chemical Company (EMN), reported an acquisition on 08/28/2025 of 2,200 Phantom Stock Units under the company Executive Deferred Compensation Plan. Each phantom unit has a value equal to one share of common stock and is payable only in cash, subject to certain acceleration and early withdrawal provisions. The report shows a deemed price of $68.18 per share and lists 2,200 units beneficially owned following the transaction, held directly. The Form 4 was signed by Mark D. Austin by power of attorney on 08/29/2025.
Insider purchases and deferred-compensation award reported for Eastman Chemical (EMN)
Brian Travis Smith, an executive (EVP, AFP, Mfg., WWEC & HSE) reported acquiring 1,750 shares of Eastman common stock at a price of $68.34 per share, bringing his direct beneficial ownership to 16,732 shares. Separately, he was credited with 2,200 phantom stock units under the company Executive Deferred Compensation Plan; those units have a value tied to the company common stock at $68.18 per share and are payable in cash, with the report showing 2,208 underlying shares equivalent following the award. The phantom units are subject to plan terms including limited acceleration and withdrawal provisions and are payable after termination of employment. The filing reflects routine insider equity purchases and a deferred-compensation award that links pay to the issuer stock value.
James J. O'Brien, a director of Eastman Chemical Company (EMN), reported a purchase of company shares. On 08/27/2025 he acquired 1,450 shares of Common Stock at a price of $68.811 per share. After the transaction he beneficially owned 6,828 shares directly and had an indirect interest in 1,022 shares held in a revocable trust. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025.
Insider purchase reported: Eastman Chemical Company director Kim Ann Mink purchased 1,450 shares of EMN common stock on 08/27/2025 at a price of $69.3799 per share. After the transaction she beneficially owned 2,840 shares. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025. No derivative transactions or other comments are reported in the filing.
Julie Fasone, a director of Eastman Chemical Company (EMN), purchased 1,453 shares of the company's common stock on 08/27/2025 at a reported price of $68.8 per share. After this purchase she beneficially owned 17,546 shares in a direct ownership capacity. The Form 4 was filed as a single reporting person filing and the form was signed on behalf of Ms. Fasone by Mark D. Austin by power of attorney on 08/28/2025. The report discloses no derivative transactions and provides no additional remarks.
Eric L. Butler, identified as a director of Eastman Chemical Co. (EMN), reported a purchase of 3,000 shares of Common Stock on 08/27/2025 at a price of $68.6525 per share. Following the transaction, the filing reports 9,330 shares beneficially owned, held directly. The Form 4 was signed by Power of Attorney Mark D. Austin on 08/28/2025.
Brett D. Begemann, a director of Eastman Chemical Company (EMN), reported a purchase of 1,500 shares of the issuer's common stock on 08/27/2025 at a reported price of $68.285 per share. After the transaction, Mr. Begemann beneficially owned 9,520 shares. The Form 4 was signed on behalf of Mr. Begemann by Mark D. Austin under power of attorney on 08/28/2025.